Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
Hamee
3134
River Eletec
6666
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -2.61%31.39B | -2.74%129.14B | -5.09%31.84B | -6.89%31.68B | 1.26%33.4B | -0.01%32.23B | -3.94%132.78B | -0.36%33.54B | -3.58%34.03B | -3.94%32.98B |
Cost of revenue | -6.66%23.33B | -3.93%98.64B | -7.96%24.07B | -8.34%23.86B | 1.05%25.72B | -0.20%24.99B | -0.90%102.68B | -0.78%26.16B | -2.59%26.03B | -0.71%25.45B |
Gross profit | 11.41%8.06B | 1.32%30.5B | 5.09%7.76B | -2.20%7.83B | 2.01%7.68B | 0.65%7.23B | -13.02%30.1B | 1.15%7.39B | -6.66%8B | -13.48%7.53B |
Operating expense | 9.85%5.72B | -8.37%22.41B | -2.57%6.15B | 0.37%5.92B | -19.15%5.13B | -11.71%5.21B | -3.21%24.46B | -3.50%6.31B | -4.05%5.9B | 3.64%6.35B |
Staff costs | ---- | -1.87%11.15B | ---- | ---- | ---- | ---- | 1.18%11.36B | ---- | ---- | ---- |
Selling and administrative expenses | ---- | -13.55%7.21B | ---- | ---- | ---- | ---- | 5.05%8.34B | ---- | ---- | ---- |
-Selling and marketing expense | ---- | -6.60%990M | ---- | ---- | ---- | ---- | -10.55%1.06B | ---- | ---- | ---- |
-General and administrative expense | ---- | -14.56%6.22B | ---- | ---- | ---- | ---- | 7.79%7.28B | ---- | ---- | ---- |
Depreciation and amortization | ---- | -4.24%1.11B | ---- | ---- | ---- | ---- | 4.33%1.16B | ---- | ---- | ---- |
-Depreciation | ---- | -4.24%1.11B | ---- | ---- | ---- | ---- | 4.33%1.16B | ---- | ---- | ---- |
Rent and land expenses | ---- | -10.15%1.15B | ---- | ---- | ---- | ---- | -2.81%1.28B | ---- | ---- | ---- |
Other operating expenses | ---- | -22.63%1.8B | ---- | ---- | ---- | ---- | -36.76%2.33B | ---- | ---- | ---- |
Operating profit | 15.42%2.34B | 43.37%8.08B | 50.09%1.61B | -9.42%1.91B | 116.34%2.54B | 57.39%2.02B | -39.58%5.64B | 41.13%1.07B | -13.28%2.1B | -54.28%1.18B |
Net non-operating interest income (expenses) | 24.35%143M | 389.80%480M | 190.57%154M | 221.62%119M | 268.00%92M | 776.47%115M | 113.04%98M | -7.02%53M | 331.25%37M | 47.06%25M |
Non-operating interest income | 23.36%169M | 178.11%559M | 138.36%174M | 131.67%139M | 113.73%109M | 705.88%137M | 31.37%201M | -14.12%73M | 566.67%60M | 15.91%51M |
Non-operating interest expense | 18.18%26M | -23.30%79M | 0.00%20M | -13.04%20M | -34.62%17M | -35.29%22M | -3.74%103M | -28.57%20M | -8.00%23M | -3.70%26M |
Net investment income | -46.44%534M | 30.86%1.18B | 450.93%379M | -59.16%-417M | -63.99%224M | 52.91%997M | 210.65%904M | -167.50%-108M | -13,000.00%-262M | 954.24%622M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | 5M | 0 | 0 | |||||||
Income from associates and other participating interests | 67.44%-14M | 69.74%-46M | 164.63%53M | 106.25%2M | -3,000.00%-58M | -7.50%-43M | -210.14%-152M | -415.38%-82M | -346.15%-32M | -95.56%2M |
Special income (charges) | -109.68%-65M | -221.38%-653M | -109.49%-45M | -1,284.85%-457M | -200.84%-120M | -40.91%-31M | 144.76%538M | 380.47%474M | 96.71%-33M | 221.62%119M |
Less:Other special charges | 109.68%65M | 165.37%653M | 104.81%45M | 1,284.85%457M | 200.84%120M | 40.91%31M | -193.28%-999M | -653.25%-935M | -96.33%33M | -221.62%-119M |
Less:Write off | ---- | --0 | ---- | ---- | ---- | ---- | 251.91%461M | ---- | ---- | ---- |
Other non-operating income (expenses) | -42.55%27M | -64.02%86M | -323.08%-58M | -47.06%36M | -33.70%61M | -11.32%47M | 51.27%239M | -13.33%26M | -20.93%68M | 607.69%92M |
Income before tax | -4.60%2.97B | 25.71%9.13B | 45.79%2.1B | -36.84%1.19B | 35.29%2.74B | 61.84%3.11B | 569.01%7.27B | 115.21%1.44B | 25.23%1.88B | -26.09%2.03B |
Income tax | -0.13%769M | -26.23%1.48B | -83.31%212M | 392.65%335M | -60.99%165M | 210.48%770M | 16.94%2.01B | 274.93%1.27B | -64.02%68M | -67.36%423M |
Net income | -6.07%2.2B | 45.57%7.65B | 1,027.54%1.88B | -52.95%853M | 60.70%2.58B | 39.81%2.34B | 260.88%5.26B | 101.91%167M | 38.08%1.81B | 10.93%1.6B |
Net income continuous operations | -6.07%2.2B | 45.57%7.65B | 1,027.54%1.88B | -52.95%853M | 60.70%2.58B | 39.81%2.34B | 260.88%5.26B | 101.91%167M | 38.08%1.81B | 10.93%1.6B |
Noncontrolling interests | -42.86%-10M | 69.84%107M | 151.06%24M | 492.31%102M | -111.11%-12M | -125.00%-7M | -83.93%63M | -118.08%-47M | 29.73%-26M | -12.90%108M |
Net income attributable to the company | -5.92%2.21B | 45.27%7.54B | 768.69%1.86B | -59.16%751M | 73.11%2.59B | 42.61%2.35B | 241.92%5.19B | 102.38%214M | 36.22%1.84B | 13.17%1.5B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | -5.92%2.21B | 45.27%7.54B | 768.69%1.86B | -59.16%751M | 73.11%2.59B | 42.61%2.35B | 241.92%5.19B | 102.38%214M | 36.22%1.84B | 13.17%1.5B |
Gross dividend payment | ||||||||||
Basic earnings per share | -5.59%48.34 | 50.54%164.59 | 628.01%40.55 | -58.15%16.38 | 81.02%56.46 | 53.16%51.2 | 247.78%109.33 | 103.07%5.57 | 43.42%39.14 | 16.77%31.19 |
Diluted earnings per share | -5.59%48.34 | 50.54%164.59 | 768.31%40.55 | -58.15%16.38 | 81.02%56.46 | 53.16%51.2 | 247.78%109.33 | 102.57%4.67 | 43.42%39.14 | 16.78%31.19 |
Dividend per share | 0 | 25.00%50 | 50.00%30 | 0 | 0.00%20 | 0 | 0.00%40 | 0.00%20 | 0 | 0.00%20 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |